HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Haft Bagh Highway, Kerman, 7616913555, Iran.
Centre On Drug Policy Evaluation, St. Michael's Hospital, Toronto, ON, M5B 1W8, Canada.
Harm Reduct J. 2022 Aug 20;19(1):93. doi: 10.1186/s12954-022-00675-9.
Incarcerated people are at an increased risk of contracting HIV and transmitting it to the community post-release. In Iran, HIV epidemics inside prisons were first detected in the early 1990s. We assessed the HIV prevalence and its correlates, as well as the continuum of care among incarcerated people in Iran from 2010 to 2017.
We used data collected in three national bio-behavioral surveillance surveys among incarcerated individuals in 2010 (n = 4,536), 2013 (n = 5,490), and 2017 (n = 5,785) through a multistage cluster sampling approach. HIV was tested by the ELISA method in 2010 and 2013 surveys and rapid tests in 2017. Data on demographic characteristics, risky behaviors, HIV testing, and treatment were collected via face-to-face interviews. HIV prevalence estimates along with 95% confidence intervals (CI) were reported. Using data from the 2017 round, multivariable logistic regression models were built to assess the correlates of HIV sero-positivity and conduct HIV cascade of care analysis.
The HIV prevalence was 2.1% (95% CI: 1.2%, 3.6%) in 2010, 1.7% (95% CI: 1.3%, 2.1%) in 2013, and 0.8% (95% CI: 0.6%, 1.1%) in 2017 (trend P value < 0.001). Among people with a history of injection drug use, HIV prevalence was 8.1% (95% CI: 4.6%, 13.8%) in 2010, 6.3% (95% CI: 4.8%, 8.3%) in 2013, and 3.9% (95% CI: 2.7%, 5.7%) in 2017. In 2017, 64% (32 out of 50) of incarcerated people living with HIV were aware of their HIV status, of whom 45% (9 out of 20) were on antiretroviral therapy, and of whom 44% (4 out of 9) were virally suppressed (< 1000 copies/ml).
While HIV prevalence has decreased among incarcerated people in Iran, their engagement in the HIV continuum of care is suboptimal. Further investments in programs to link incarcerated people to HIV care and retain them in treatment are warranted.
在押人员感染艾滋病毒并在释放后将其传播给社区的风险增加。在伊朗,监狱内的艾滋病毒疫情最早是在 20 世纪 90 年代初发现的。我们评估了 2010 年至 2017 年期间伊朗在押人员中的艾滋病毒流行率及其相关因素,以及护理的连续性。
我们使用了通过多阶段聚类抽样方法在 2010 年(n=4536)、2013 年(n=5490)和 2017 年(n=5785)三次全国生物行为监测调查中收集到的数据。2010 年和 2013 年的调查采用酶联免疫吸附试验(ELISA)方法检测 HIV,2017 年采用快速检测方法。通过面对面访谈收集人口统计学特征、危险行为、HIV 检测和治疗数据。报告了艾滋病毒流行率估计值及其 95%置信区间(CI)。利用 2017 年的数据,建立多变量逻辑回归模型,评估 HIV 血清阳性的相关因素,并进行 HIV 护理连续体分析。
2010 年 HIV 流行率为 2.1%(95%CI:1.2%,3.6%),2013 年为 1.7%(95%CI:1.3%,2.1%),2017 年为 0.8%(95%CI:0.6%,1.1%)(趋势 P 值<0.001)。在有注射吸毒史的人群中,2010 年 HIV 流行率为 8.1%(95%CI:4.6%,13.8%),2013 年为 6.3%(95%CI:4.8%,8.3%),2017 年为 3.9%(95%CI:2.7%,5.7%)。2017 年,50 名感染艾滋病毒的在押人员中有 64%(32 人)知晓自己的艾滋病毒状况,其中 45%(9 人)接受了抗逆转录病毒治疗,其中 44%(4 人)病毒得到了抑制(<1000 拷贝/ml)。
虽然伊朗在押人员中的艾滋病毒流行率有所下降,但他们参与艾滋病毒护理连续体的情况并不理想。有必要进一步投资于将在押人员与艾滋病毒护理联系起来并留住他们接受治疗的方案。